PGEN Precigen Inc

0.00 (0.0%)
Pre Market
Last Updated: 04:00:09
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 0
Bid Price 1.36
Ask Price 1.47
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Precigen Inc PGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.42 04:00:09
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 0.805 - 2.288
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.42 USD

Precigen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
362.79M 255.48M - 26.91M 28.32M 0.11 12.91
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Precigen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No PGEN Message Board. Create One! See More Posts on PGEN Message Board See More Message Board Posts

Historical PGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.401.501.271.39865,1920.021.43%
1 Month1.791.831.241.491,095,853-0.37-20.67%
3 Months1.101.87991.061.491,633,5000.3229.09%
6 Months0.921.87990.86121.341,431,0380.5054.35%
1 Year2.142.2880.8051.441,457,678-0.72-33.64%
3 Years3.5611.100.8053.661,422,015-2.14-60.11%
5 Years5.1311.100.8053.711,438,937-3.71-72.32%

Precigen Description

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals; Exemplar, and Trans Ova. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.